Media

BONESUPPORT HOLDING AB (publ) – Invitation to conference call and webcast for Interim report Q2 2024

Precirix Partners with Orchestra Life Sciences to Expand Access to Radioisotope Lead-212 (Pb-212)

Carisma Therapeutics Announces Changes to its Board of Directors

The market submission for CERAMENT® V in the US will be a 510(k)

Oncopeptides selects first candidate drug from its SPiKE platform

Carisma Therapeutics Granted FDA Fast Track Designation for CT-0525 for the Treatment of HER2-overexpressing Solid Tumors

EUROAPI and Priothera enter into CDMO collaborationto advance oncology project

Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051

BONESUPPORT – CERAMENT® contributes to fewer amputations – new data from Australia

Precirix to present clinical study results of its HER2-targeting CAM-H2 compound at the 2024 SNMMI annual meeting